NASDAQ:RIGL

Rigel Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RIGL

*Your capital is at risk

$30.30

+0.280 (+0.93%)

At Close: Jun 03, 2026

Rigel Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 31.92. In total, the insiders bought 755.4K and sold 143.43K RIGL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	31.92
● Buy	755.4K shares
● Sell	143.43K shares
82% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 20, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 31.92. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 01, 2026 Buy	Stock Option (right to buy) A-Award	Miller Michael Patrick Director	Director	12 000 Value: $418.3K
Feb 01, 2026 Buy	Common Stock	Miller Michael Patrick Director	Director	0 Value: $0
Feb 01, 2026 Buy	Stock Option (right to buy)	Miller Michael Patrick Director	Director	625 Value: $10.0K
Jan 26, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Rodriguez Raul R CEO, President	CEO / President	40 000 Value: $1.10M
Jan 26, 2026 Sell	Common Stock F-InKind	Rodriguez Raul R CEO, President	CEO / President	35 211 Value: $1.30M
Jan 26, 2026 Sell	Common Stock F-InKind	Rodriguez Raul R CEO, President	CEO / President	35 424 Value: $1.31M
Jan 26, 2026 Buy	Common Stock M-Exempt	Rodriguez Raul R CEO, President	CEO / President	40 000 Value: $1.10M
Jan 26, 2026 Buy	Common Stock M-Exempt	Rodriguez Raul R CEO, President	CEO / President	40 000 Value: $1.10M
Dec 22, 2025 Buy	Employee Stock Option (right to buy) M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	2 846 Value: $68.9K
Dec 22, 2025 Buy	Common Stock M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 987 Value: $39.7K
Dec 22, 2025 Buy	Common Stock M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	2 846 Value: $68.9K
Dec 22, 2025 Buy	Common Stock M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 667 Value: $31.2K
Dec 22, 2025 Buy	Employee Stock Option (right to buy) M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 987 Value: $39.7K
Dec 22, 2025 Buy	Employee Stock Option (right to buy) M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 667 Value: $31.2K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Santos David A EVP, Chief Commercial Officer	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Rojkjaer Lisa EVP, Chief Medical Officer	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Furey Raymond J. EVP, GC, Cco & Corp Sec	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Rodriguez Raul R CEO, President	CEO / President	31 700 Value: $712.9K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Rodriguez Raul R CEO, President	CEO / President	31 700 Value: $712.9K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Furey Raymond J. EVP, GC, Cco & Corp Sec	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Rojkjaer Lisa EVP, Chief Medical Officer	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Santos David A EVP, Chief Commercial Officer	Officer	7 394 Value: $166.3K
Sep 15, 2025 Buy	Employee Stock Option (right to buy) A-Award	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	7 394 Value: $166.3K
May 23, 2025 Buy	Common Stock A-Award	Wasman Jane Director	Director	2 500 Value: $47.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RIGEL PHARMACEUTICALS

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...

Read Full Profile Here